Isoniazid

Generic Name: Isoniazid

Brand Names: Isonarif, Isotamine, Isotamine B, Rifamate, Rifater

Drug Type: Small Molecule

Chemical Formula: C_₆H_₇N_₃O

CAS Number: 54-85-3

Unique Ingredient Identifier: V83O1VOZ8L

Background: Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.

Indication: Isoniazid is used for the treatment of all forms of tuberculosis in which organisms are susceptible. It is also used in combination with rifampin and pyrazinamide.

Associated Conditions: Active Tuberculosis, Mycobacterium kansasii infection, Late phase Tuberculosis

Clinical Trials

The Prophylaxis of Tuberculosis According to TSPOT Results After Kidney Transplantation

Not Applicable

Conditions: Tuberculosis
Kidney Transplant Infection
Isoniazid Toxicity

Interventions: Other: without any additional anti-tuberculosis treatment
Drug: Isoniazid

First Posted Date: 2022-02-22

Last Posted Date: 2022-04-04

Lead Sponsor: West China Hospital

Target Recruit Count: 303

Registration Number: NCT05249699

Pharmacogenetics-guided Isoniazid Dosing in TB-HIV

Phase 2

Conditions: Tuberculosis

Interventions: Drug: Isoniazid Tablets

First Posted Date: 2021-11-18

Last Posted Date: 2022-01-25

Lead Sponsor: Makerere University

Target Recruit Count: 40

Registration Number: NCT05124678

Locations: 🇺🇬
Infectious Diseases Institute, Kampala, Uganda

Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV

Phase 1

Recruiting

Conditions: Pregnancy
Tuberculosis Infection
HIV Seropositivity

Interventions: Drug: Rifapentine
Drug: Isoniazid

First Posted Date: 2021-11-16

Last Posted Date: 2024-03-18

Lead Sponsor: The Aurum Institute NPC

Target Recruit Count: 252

Registration Number: NCT05122026

Locations: 🇿🇦
The Aurum Institute: Tembisa Clinical Research Centre, Tembisa, Gauteng, South Africa
🇿🇦
Peri Natal HIV Research Unit - Klerksdorp Tshepong Hospital, Klerksdorp, North-West, South Africa
🇿🇦
FAMily Centre for Research with Ubuntu (FAMCRU), Cape Town, South Africa

Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients

Active, not recruiting

Conditions: Tuberculosis, Pulmonary

Interventions: Drug: Isoniazid
Drug: Rifampicin
Drug: Pyrazinamide
Drug: Ethambutol
Drug: Moxifloxacin

First Posted Date: 2021-09-16

Last Posted Date: 2024-01-05

Lead Sponsor: Tuberculosis Research Centre, India

Target Recruit Count: 550

Registration Number: NCT05047055

Locations: 🇮🇳
National Institute for Research in Tuberculosis, Chennai, Tamilnadu, India

Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)

Phase 2

Active, not recruiting

Conditions: Tuberculosis
Pulmonary Tuberculosis
HIV Coinfection

Interventions: Drug: Isoniazid
Drug: Rifampicin
Drug: Ethambutol
Drug: Pyrazinamide
Drug: Metformin hydrochoride

First Posted Date: 2021-06-18

Last Posted Date: 2025-04-23

Lead Sponsor: University of Massachusetts, Worcester

Target Recruit Count: 112

Registration Number: NCT04930744

Locations: 🇿🇦
Tembisa Clinical Research Centre-The Aurum Institute, Johannesburg, Gauteng, South Africa
🇿🇦
Isango Lethemba TB Research Unit, Port Elizabeth, South Africa

Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation

Phase 4

Completed

Conditions: Latent Tuberculosis
Diabetes Mellitus, Type 2

Interventions: Drug: Rifampicin 300 Mg Oral Capsule
Drug: Isoniazid 300 Mg ORAL TABLET

First Posted Date: 2021-04-05

Last Posted Date: 2023-05-16

Lead Sponsor: Herlev and Gentofte Hospital

Target Recruit Count: 32

Registration Number: NCT04830462

Locations: 🇩🇰
Herlev-Gentofte Hospital, Copenhagen, Denmark

Healing of Ischemic Leg Ulcers in Patients Treated With iSONIAzid

Phase 2

Withdrawn

Conditions: Arterial Leg Ulcer

Interventions: Drug: Placebo
Drug: Isoniazid 300 milligram

First Posted Date: 2021-03-17

Last Posted Date: 2021-03-19

Lead Sponsor: Pharma 2100

Registration Number: NCT04802928

Locations: 🇩🇰
Bispebjerg Hospital, Copenhagen, Denmark

Preventive Treatment Of Latent Tuberculosis Infection In People With Diabetes Mellitus

Phase 3

Recruiting

Conditions: Diabetes Mellitus
Tuberculosis

Interventions: Drug: Isoniazid and Rifapentine (INH-RPT)
Drug: Placebo

First Posted Date: 2020-10-23

Last Posted Date: 2023-03-29

Lead Sponsor: Dr. Nyanda Elias Ntinginya

Target Recruit Count: 3000

Registration Number: NCT04600167

Locations: 🇺🇬
Martyrs Hospital Lubaga, Kampala, Uganda
🇺🇬
Makerere University, Kampala, Uganda
🇹🇿
Mbeya zonal referral hospital, Mbeya, Tanzania

and more 1 locations

Vaginal Misoprostol and Dinoprostone and Isonicotinic Acid Hydrazide Prior to Copper Intrauterine Device Insertion

Not Applicable

Conditions: IUCD Complication

Interventions: Drug: dinoprostine
Drug: Isonicotinic Acid Hydrazide
Drug: misoprostol

First Posted Date: 2020-08-10

Last Posted Date: 2020-08-18

Lead Sponsor: Aswan University Hospital

Target Recruit Count: 200

Registration Number: NCT04505943

Locations: 🇪🇬
Aswan University Hospital, Aswan, Egypt

Rosuvastatin Evaluation as a Tuberculosis Treatment Adjunct

Phase 2

Conditions: Pulmonary Tuberculosis

Interventions: Drug: Rifampicin
Drug: Rosuvastatin 10mg
Drug: Isoniazid
Drug: Pyrazinamide
Drug: Ethambutol

First Posted Date: 2020-08-07

Last Posted Date: 2020-08-07

Lead Sponsor: National University Hospital, Singapore

Target Recruit Count: 154

Registration Number: NCT04504851

Locations: 🇺🇬
Joint Clinical Research Centre, Kampala, Uganda
🇻🇳
Vietnam Military Medical University, Hanoi, Vietnam
🇵🇭
Tropical Disease Foundation, Makati City, Philippines

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy